Advertisement

Erkrankungen von Knochen, Muskeln und Gelenken

  • Johann O. Schröder
  • Ulf Müller-Ladner
  • Schaumburger Jens
  • Grifka Joachim
  • Woenckhaus Ulrike
  • Fleck Martin
  • Hans-Wolfram Ulrich
  • Andrea Gödde
  • Peter Lamprecht
  • Christian Kneitz
  • Hans-Peter Tony
  • Johann O. Schröder
  • Thomas Glück
  • Jürgen Wollenhaupt
  • Pontus Harten
  • Johannes Von Kempis

Zusammenfassung

Unter dem Überbegriff Osteopathien werden verschiedene Knochenerkrankungen zusammengefasst. Man differenziert die metabolischen Osteopathien von zirkulatorischen Störungen (Osteonekrosen) und toxischen, infektiösen sowie neoplastischen Osteopathien. Zu den metabolischen Osteopathien wird eine Reihe von Krankheiten gezählt, deren Ursachen sehr unterschiedlich sind, z. B. Hyper- und Hypoparathyreoidismus. Im nachfolgenden Kapitel wird vor allem auf Osteoporose und Osteomalazie eingegangen, der M. Paget ist in Kap. 7.2 ausführlich dargestellt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bilezikian JP, Raisz LG, Rhodan GA (1996) Principles of bone biology. Academic Press, San Diego London Boston New York Sydney Tokyo TorontoGoogle Scholar
  2. Consensus Development Statement (1997) Who are candidates for prevention and treatment for osteoporosis? Osteoporosis Int 7: 1–6Google Scholar
  3. Dambacher MA, Neff M (2001) Erworbene Skelettsystemerkrankungen. In: Wirth CJ (Hrsg) Praxis der Orthopädie. Thieme, Stuttgart New York, S 371–414Google Scholar
  4. Ettinger B, Black DM, Mitlak BH et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 282: 637–645PubMedCrossRefGoogle Scholar
  5. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurence of osteoporotic fractures. BMJ 12: 1254–1259CrossRefGoogle Scholar
  6. McClung MR, Geusens P, Miller PD et al. (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344: 333–340PubMedCrossRefGoogle Scholar
  7. Neer RM, Arnaud CD, Zanchetta JR et al. (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434–1441PubMedCrossRefGoogle Scholar
  8. NIH Consensus Development Panel (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285: 785–795CrossRefGoogle Scholar
  9. Seibel MJ, Stracke H (1997) Metabolische Osteopathien. Schattauer, StuttgartGoogle Scholar
  10. Bone HG, Kleerekoper M (1992) Clinical review 39: Paget’s disease of bone. J Clin Endocrinol Metab 75: 1179–1182Google Scholar
  11. Drake WM, Kendler DL, Brown JB (2001) Consensus statement on the modern therapy of Paget’s disease of bone from a western osteoporosis alliance symposium. Clin Ther 23: 620–626PubMedCrossRefGoogle Scholar
  12. Feldkamp J, Scherbaum WA (2001) Risedronsäure, neues Bisphosphonat zur Therapie und Prophylaxe der Osteoporose. Arzneimitteltherapie 19: 38–44Google Scholar
  13. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88: 2961–2978PubMedCrossRefGoogle Scholar
  14. Siris ES (1999) Goals of treatment for Paget’s disease of bone. J Bone Miner Res 14 (Suppl 2): 49–52PubMedCrossRefGoogle Scholar
  15. Baitner AC, Maurer SG, Gruen MB, Di Cesare PE (2000) The genetic basis of the osteochondrodysplasias. J Pediatr Orthop 20: 594–605PubMedCrossRefGoogle Scholar
  16. Candelierer G, Glorieux FH, Prud’Homme J, St.-Arnaud R (1995) Increased expression of the c-fos proto-oncogene in bone from patients with fibrous dysplasia. N Engl J Med 332: 1546–1551Google Scholar
  17. Tilstra DJ, Byers PH (1994) Molecular basis of hereditary dis- orders of connective tissue. Annu Rev Med 45: 149–163PubMedCrossRefGoogle Scholar
  18. Vanhoenacker FM, De Beuckeleer LH, Van Hul W, Balemans W, Tan GJ, Hill SC, De Schepper AM (2000) Sclerosing bone dysplasias: genetic and radiolclinical features. Eur Radiol 10: 1423–1433PubMedCrossRefGoogle Scholar
  19. Brandt KD, Doherty M, Lohmander LS (1998) Osteoarthritis. Oxford University Press, OxfordGoogle Scholar
  20. Coventry MB (1993) Proximal tibial osteotomy. J Bone Jt Surg 75-A: 196–201Google Scholar
  21. Fuchs S (1999) Bedeutung der Tibiakopfumstellungsosteotomie im Zeitalter von Endoprothesen. Z Orthop 37: 153–258Google Scholar
  22. Hassenpflug J, von Haugwitz A, Hahne HJ (1998) Long term results of tibial head osteotomy. Z Orthop 36: 154–161CrossRefGoogle Scholar
  23. Tönnis D, Heinecke A (1999) Acetabular and femoral anteversion: relationship with osteoarthritis of the hip. J Bone Joint Surg Am 81: 1747–1770Google Scholar
  24. Hochberg MC (2001) What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist’s perspective. Clin Exp Rheumatol 19 (Suppl 25): S15 - S22PubMedGoogle Scholar
  25. Jackson LM, Hawkey CJ (2000) COX-2 selective nonsteroidal anti-inflammatory drugs: do they really offer any advantages? Drugs 59: 1207–1216PubMedCrossRefGoogle Scholar
  26. Cheung HS (2000) Calcium crystal effects on the cells of the joint: implications for pathogenesis of disease. Curr Opin Rheumatol 12: 223–227PubMedCrossRefGoogle Scholar
  27. Fam AG (2000) What is new about crystals other than monosodium urate? Curr Opin Rheumatol 12: 228–234PubMedCrossRefGoogle Scholar
  28. Dihlmann W (1987) Gelenke - Wirbelverbindungen. Klinische Radiologie einschließlich Computertomographie - Diagnose, Differentialdiagnose, 3. Aufl. Thieme, Stuttgart New YorkGoogle Scholar
  29. Donatto KC (1998) Orthopedic management of septic arthritis. Rheum Dis Clin North Am 24: 275–286CrossRefGoogle Scholar
  30. Goldenberg DL (1998) Septic Arthritis. Lancet 351: 197–202CrossRefGoogle Scholar
  31. Groß DM, Forsthuber T, Tary-Lehmann M et al. (1998) Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme-arthritis. Science 281: 703–706PubMedCrossRefGoogle Scholar
  32. Gupta MN, Sturrock RD, Field M (2001) A prospective 2-year study of 75 patients with adult-onset septic arthritis. Rheumatology 40: 24–30PubMedCrossRefGoogle Scholar
  33. Hogan CJ, Fang GD, Scheid WM, Linden J, Diduch DR (2001) Inhibiting the inflammatory response in joint sepsis. Arthroscopy 17: 311–315PubMedCrossRefGoogle Scholar
  34. Jalava J, Skurnik M, Toivanen A, Toivanen P, Eerola E (2001) Bacterial PCR in the diagnosis of joint infection. Ann Rheum Dis 60: 287–289PubMedCrossRefGoogle Scholar
  35. Krijnen P, Kaandorp CJ, Steyerberg EW, van Schaardenburg D, Moens HJ, Habbema JD (2001) Antibiotic prophylaxis for haematogenous bacterial arthritis in patients with joint disease: a cost effectiveness analysis. Ann Rheum Dis 60: 359–366PubMedCrossRefGoogle Scholar
  36. Stutz G, Kuster MS, Kleinstuck F, Gachter A (2000) Arthroscopic management of septic arthritis: stages of infection and results. Knee Surg Sports Traumatol Arthrosc 8: 270–274PubMedCrossRefGoogle Scholar
  37. Thaler SJ, Maguire JH (1998) Infectious arthritis. In: Fauci AS, Braunwald E, Isselbacher KJ et al. (eds) Harrison’s principles of internal medicine, 14. edn. McGraw-Hill, New York-TorontoGoogle Scholar
  38. van der Heijden IM, Wilbrink B, Schouls LM, van Embden JD, Breedveld FC, Tak PP (1999) Detection of mycobacteria in joint samples from patients with arthritis using a genus-specific polymerase chain reaction and sequence analysis. Rheumatology 38: 547–553CrossRefGoogle Scholar
  39. Verdrengh M, Tarkowski A (2000) Role of macrophages in Staphylococcus aureus-induced arthritis and sepsis. Arthritis Rheum 43: 2276–2282PubMedCrossRefGoogle Scholar
  40. Wormser GP, Nadelmann RB, Dattwyler RJ et al. (2000) Practice guidelines for the treatment of lyme disease. Clin Infect Dis 31 (Suppl 1): 51–514Google Scholar
  41. Zeidler H, Zacher J, Hiepe F (Hrsg) (2001) Interdisziplinäre klinische Rheumatologie: Innere Medizin - Orthopädie - Immunologie. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  42. Breedfeld FC, Dayer JM (2000) Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 59: 841–849CrossRefGoogle Scholar
  43. Choy EH, Panayi GS (2001) Cytokine pathways and joint inflam- mation in rheumatoid arthritis. N Engl J Med 344: 907–916PubMedCrossRefGoogle Scholar
  44. Crofford LJ, Lipsky PE, Brooks P, Abramson SB, Simon LS, Van De Putte LB (2000) Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum 43: 4–13PubMedCrossRefGoogle Scholar
  45. Firestein GS (2001) Etiology and pathogenesis of rheumatoid arthritis. In: Ruddy S, Harris ED, Sledge CB (eds) Kelley’s textbook of rheumatology. WB Saunders, PhiladelphiaGoogle Scholar
  46. Furst DE et al. (2002) Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases. Ann Rheum Dis 61 (Suppl II): ii2-ii7Google Scholar
  47. Harris ED (2001) Clinical features of rheumatoid arthritis. In: Ruddy S, Harris ED, Sledge CB (eds) Kelley’s textbook of rheumatology. WB Saunders, PhiladelphiaGoogle Scholar
  48. Markham A, Lamb HM (2000) Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 59: 1341–1359CrossRefGoogle Scholar
  49. O’Dell JR, Scott DL (1999) Rheumatoid arthritis: new developments in the use of existing therapies. Rheumatology 38 (Suppl 2): 24–26PubMedGoogle Scholar
  50. Plant MJ, Jones PW, Saldatvala J, Oilier WE, Dawes PT (1998) Patterns of radiological progression in early rheumatoid arthritis: results of an 8 year prospective study. J Rheumatol 25: 417–426PubMedGoogle Scholar
  51. Ryan L, Brooks P (1999) Disease modifying antirheumatic drugs. Curr Opin Rheumatol 11: 161–166PubMedCrossRefGoogle Scholar
  52. Spencer-Green G (2000) Etanercept (Enbrel): update on therapeutic use. Ann Rheum Dis 59 (Suppl 1): i46 - i49PubMedCrossRefGoogle Scholar
  53. Taylor PC (2001) Anti-tumor necrosis factor therapies. Curr Opin Rheumatol 13: 164–169PubMedCrossRefGoogle Scholar
  54. Verhoeven AC, Boers M, Tugwell P (1998) Combination therapy in rheumatoid arthritis: An updated systematic review. Br J Rheumatol 37: 1102–1109Google Scholar
  55. Bywaters EGL (1971) Still’s disease in the adult. Ann Rheum Dis 31: 121–133CrossRefGoogle Scholar
  56. Cush JJ, Medsger TA Jr, Christy WC et al. (1987) Adult-onset Still’s disease. Clinical course and outcome. Arthritis Rheum 30: 186–194Google Scholar
  57. Delpech M, Grateau G (2001) Genetically determined recurrent fevers. Curr Opin Immunol 13: 539–542PubMedCrossRefGoogle Scholar
  58. Fautrel B, Borget C, Rozenberg S et al. (1999) Corticosteroid sparing effect of low dose methotrexate treatment in adult Still’s disease. J Rheumatol 26: 373–378PubMedGoogle Scholar
  59. Fautrel B, Le Moel G, Saint-Marcoux B et al. (2001) Diagnostic value of ferritin and glycosylated ferritin in adult onset Still’s disease. J Rheumatol 28: 322–329PubMedGoogle Scholar
  60. Khraishi M, Fam AG (1991) Treatment of fulminant adult Still’s disease with intravenous pulse methylprednisolone therapy. J Rheumatol 18: 1088–1090PubMedGoogle Scholar
  61. Pouchot J, Sampalis JS, Beaudet F et al. (1991) Adult Still’s disease: Manifestations, disease course, and outcome in 62 patients. Medicine 70: 118–136PubMedCrossRefGoogle Scholar
  62. Yamaguchi M, Ohta A, Tsunematsu T et al. (1992) Preliminary criteria for classification of adult Still’s disease. J Rheumatol 19: 424–430PubMedGoogle Scholar
  63. Adam D, Scholz H, Helmerking M (2000) Short-course antibiotic treatment of 4782 culture-proven cases of group A streptococcal tonsillopharyngitis and incidence of poststreptococcal sequelae. J Infect Dis 182: 509–516PubMedCrossRefGoogle Scholar
  64. Albert DA, Harel L, Karrison T (1995) The treatment of rheuma- tic carditis: a review and meta-analysis. Medicine 74: 1–12PubMedCrossRefGoogle Scholar
  65. Bisno AL (2000) Nonsuppurative poststreptococcal sequelae: Rheumatic fever and glomerulonephritis. In: Mandell GL, Bennett JE, Dolin R (eds) Principles and practice of infectious diseases, 5th edn. Churchill Livingstone, Philadelphia, p 2117–2128Google Scholar
  66. Del Mar CB, Glasziou PP, Spinks AB (1/2002) Antibiotics for sore throat (Cochrane Review). In: The Cochrane Library. Oxford: Update SoftwareGoogle Scholar
  67. Gibofsky A, Kerwar S, Zabriskie JB (1998) Rheumatic fever. The relationship between host, microbe, and genetics. Rheum Dis Clin N Am 24: 237–259Google Scholar
  68. Lue HC, Wu MH, Wang JK, Wu FF, Wu YN (1994) Long-term outcome of patients with rheumatic fever receiving benzathine penicillin G prophylaxis every three weeks versus every four weeks. J Pediatr 125: 812–816PubMedCrossRefGoogle Scholar
  69. Oen K (2000) Comparative epidemiology of the rheumatic diseases in children. Curr Opin Rheumatol 12: 410–414PubMedCrossRefGoogle Scholar
  70. Olivier C (2000) Rheumatic fever–is it still a problem? J Antimicrob Chemother 45: 13–21PubMedCrossRefGoogle Scholar
  71. Special writing group of the committee on rheumatic fever, endocarditis and Kawasaki disease of the council on cardiovascular disease in the young of the American Heart Association (1992) Guidelines for the diagnosis of rheumatic fever. Jones criteria,1992 update. JAMA 2069–2073Google Scholar
  72. Brandt J, Haibel H, Comely D et al. (2000) Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43: 1346–1352PubMedCrossRefGoogle Scholar
  73. Calin A, Porta J, Fries JF, Schurmann DJ (1977) Clinical history as a screening test for ankylosing spondylitis. JAMA 237: 2613–2614PubMedCrossRefGoogle Scholar
  74. Dougados M, van der Linden S, Juhlin R et al (1991) The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34: 1218–1227PubMedCrossRefGoogle Scholar
  75. Goie HS, Steven MM, van der Linden S, Cats A (1985) Evaluation of diagnostic criteria for ankylosing spondylitis: a comparison of the Rome, New York and modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis. Br J Rheumatol 24: 242–249Google Scholar
  76. Mau W, Zeidler H, Mau R et al. (1990) Evaluation of early diagnostic criteria for ankylosing spondylitis in a 10 year follow-up. Z Rheumatol 49: 82–87PubMedGoogle Scholar
  77. Olivieri I, Salvarani C, Cantini F, Ciancio G, Padula A (2001) Ankylosing spondylitis and undifferentiated spondyloarthropathies: a clinical review and description of a disease subset with older age at onset. Curr Opin Rheumatol 13: 280–284PubMedCrossRefGoogle Scholar
  78. Toivanen A (2001) Bacteria-triggered reactive arthritis: implications for antibacterial treatment. Drugs 61: 343–351PubMedCrossRefGoogle Scholar
  79. Toivanen A, Toivanen P (2000) Reactive arthritis. Curr Opin Rheumatol 12: 300–305PubMedCrossRefGoogle Scholar
  80. van der Linden S, van der Heijde D (2000) Clinical aspects, outcome assessment, and management of ankylosing spondylitis and postenteric reactive arthritis. Curr Opin Rheumatol 12: 263–268CrossRefGoogle Scholar
  81. Girolomoni G, Abeni D (2001) Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis. Arch Dermatol 137 (6): 784–785PubMedGoogle Scholar
  82. Helliwell PS, Wright V (1994) Psoriatic arthritis. In: Klippel JH, Dieppe PA (eds) Rheumatology. Mosby, St. LouisGoogle Scholar
  83. Jones G, Crotty M, Brooks P (2000) Interventions for psoriatic arthritis. Cochrane Database Syst Rev 3: CD000212Google Scholar
  84. Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3: 55–78PubMedCrossRefGoogle Scholar
  85. Mrowietz U (2001) Advances in systemic therapy for psoriasis. Clin Exp Dermatol 26: 362–367PubMedCrossRefGoogle Scholar
  86. Patel S, Veale D, Fitzgerald O, McHugh NJ (2001) Psoriatic arthri- tis-emerging concepts. Rheumatology (Oxford) 40: 243–246CrossRefGoogle Scholar
  87. Spadaro A, Riccieri V, Sili-Scavalli A, Sensi F, Taccari E, Zoppini A (1995) Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 13 (5): 589–593PubMedGoogle Scholar
  88. Veys EM, Mielants H (1994) Enteropathic arthropathies. In: Klippel JH, Dieppe PA (eds) Rheumatology. Mosby, St. LouisGoogle Scholar
  89. Zachariae H (1999) Renal toxicity of long-term ciclosporin. Scand J Rheumatol 28: 65–68PubMedCrossRefGoogle Scholar
  90. Chamot AM, Benhamou CL, Kahn MF, Beraneck L, Kaplan G, Prost A (1987) Le syndrome hyperosotse osteite (SAPHO). Resultats d’une enquete nationale: 85 observations. Rev Rhum Mal Osteoartic 187–196Google Scholar
  91. Edlund E, Johnsson U, Lidgren L, Petterson H, Sturfelt G, Svensson B et al. (1988) Palmoplantar pustulosis and sternocostoclavicular arthro-osteitis. Ann Rheum Dis 47: 809–815PubMedCrossRefGoogle Scholar
  92. Hayem G, Bouchaud-Chabot A, Benali K, Roux S, Palazzo E, Silbermann-Hoiffman O et al. (1999) SAPHO syndrome: a longterm follow-up study of 120 cases. Semin Arthritis Rheum 29: 251–256CrossRefGoogle Scholar
  93. Kahn MF, Bouvier MB, Palazzo E, Tebib J, Colson F (1991) Sternoclavicular pustulotitc osteitis (SAPHO). 20 year interval between skin and bon lesions. J Rheumatol 18: 1104–1108PubMedGoogle Scholar
  94. Kahn MF, Chamot AM (1992) SAPHO syndrome. Rheum Dis Clin N Am 18: 225–246Google Scholar
  95. Kahn MF, Khan MA (1994) The SAPHO syndrome. Ballières Clin Rheumatol 8: 333–362CrossRefGoogle Scholar
  96. Sonozaki H, Mitsui H, Miyanaga Y, Okitsu K, Igarashi M, Hayashi Yet al. (1981) Clinical features of 53 cases with pustlotic arthroosteitis. Ann Rheum Dis 40: 547–553PubMedCrossRefGoogle Scholar
  97. Van Doornum S, Barraclough D, McColl G, Wicks I (2000) SAPHO: Rare or just not recognized? Semin Arthritis Rheum 30: 70–77PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • Johann O. Schröder
  • Ulf Müller-Ladner
  • Schaumburger Jens
  • Grifka Joachim
  • Woenckhaus Ulrike
  • Fleck Martin
  • Hans-Wolfram Ulrich
  • Andrea Gödde
  • Peter Lamprecht
  • Christian Kneitz
  • Hans-Peter Tony
  • Johann O. Schröder
  • Thomas Glück
  • Jürgen Wollenhaupt
  • Pontus Harten
  • Johannes Von Kempis

There are no affiliations available

Personalised recommendations